Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to investigate whether controlled dose reduction of IL17
or IL23 inhibiting biologics is not inferior compared to usual care in psoriasis patients.
Therefore, a pragmatic, multicentre, randomized, controlled, non-inferiority study will be
carried out.
Phase:
Phase 4
Details
Lead Sponsor:
Radboud University
Collaborators:
Belgium Health Care Knowledge Centre University Hospital, Ghent ZonMw: The Netherlands Organisation for Health Research and Development